Skip Navigation

Repertoire Immune Medicines Names Anthony Coyle, Ph.D., President, Research and Development

CAMBRIDGE, MA, September 21, 2020 – Repertoire Immune Medicines, a clinical-stage biotechnology company focused on decoding and deploying the immune system across multiple major diseases, today announced that Anthony Coyle, Ph.D., has joined the company as President, Research and Development. Dr. Coyle will sit on Repertoire’s leadership team and report to Chief Executive Officer John Cox.

“Creating precision immune medicines requires the right team. Tony is a world-class immunologist, and his pioneering work at both innovative biotechnology and global pharmaceutical companies complements our mission to harness the intrinsic ability of the T cell repertoire to prevent or treat serious diseases,” said Mr. Cox. “As we progress clinical trials for our multi-clonal T cell candidates in immune-oncology, Tony’s deep expertise in cellular immunology and novel therapeutic development will help us achieve our vision of creating a new class of transformative medicines for patients.”

Dr. Coyle brings to Repertoire more than 25 years of experience in drug discovery and development, spanning academia, early-stage biotechnology companies and global pharmaceutical organizations. Most recently, he was the Co-Founder, President and CEO of Pandion Therapeutics, a clinical-stage biotechnology company focused on developing novel bispecific antibody therapeutics to locally modulate the immune system in a number of autoimmune disorders. Prior to Pandion, Dr. Coyle was a Senior Vice President and Chief Scientific Officer at Pfizer, where he launched Pfizer’s Centers for Therapeutic Innovation (CTI), a collaborative Research and Development model between Pfizer and premier academic medical centers, patient advocacy groups and the National Institute of Health. Before Pfizer, Dr. Coyle was Vice President and Global Head of Respiratory, Inflammation and Autoimmunity Research at Medimmune Biologics, a Division of AstraZeneca. Prior to his work at MedImmune, he held leadership positions at Millennium Pharmaceuticals and Glaxo Institute in Geneva.

Earlier in Dr. Coyle’s academic career, he was a postdoctoral fellow at the Institute Pasteur in Paris, National Jewish Centre for Immunology in Denver and at CIBA in Basel, Switzerland. In addition to his previous roles, Dr. Coyle has been an advisor to Flagship Pioneering and its portfolio companies since January. Dr. Coyle earned his BSc and Ph.D. in Pharmacology from King’s College, University of London.

“The ability to understand what the immune system recognizes has profound implications for human health because it is at the heart of disease. I believe Repertoire’s innovative platforms will help us understand and address the underlying mechanisms of many diseases, particularly in cancer, infectious disease and autoimmune disorders. I am thrilled to have the opportunity to join the company and develop new transformative therapies in these areas,” said Dr. Coyle.

About Repertoire Immune Medicines

Repertoire Immune Medicines is a clinical-stage biotechnology company working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is founded on the premise that the repertoire of T cell receptor-antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science. The company harnesses and deploys the intrinsic ability of T cells to prevent and cure disease. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design and clinically develop multi-clonal immune medicines. The company is currently conducting a clinical trial using autologous T cells primed against cancer antigens and tethered to IL-15. To learn more about Repertoire Immune Medicines, please visit our website: and follow us on LinkedIn and Twitter.

Media Contacts